Vaccine, tetanus toxoid, tetanus toxoid adsorbed


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : IM Active immunisation against tetanus Primary immunisation: 3 or 4 doses of 0.5 mL each, with dosing intervals depending on the product used. Booster dose: 0.5 mL every 10 years. Prophylaxis of tetanus in wound management Non-immunised patients, or if >5-10 years since last booster dose: 1 emergency dose of 0.5 mL, depending on the type of wound. Patients with minor, clean wounds who have been vaccinated within the last 5-10 years may not need emergency booster dose.
Dosage Details
Intramuscular
Active immunisation against tetanus
Adult: Primary immunisation: 3 or 4 doses of 0.5 mL each, with dosing intervals depending on the product used. Booster dose: 0.5 mL every 10 years.
Child: Primary immunisation: ≥6-8 weeks Same as adult dose.

Intramuscular
Prophylaxis of tetanus in wound management
Adult: Non-immunised patients, or if >5-10 years since last booster dose: 1 emergency dose of 0.5 mL, depending on the type of wound. Patients with minor, clean wounds who have been vaccinated within the last 5-10 years may not need emergency booster dose.
Contraindications
Hypersensitivity. Neurological disorders following previous vaccination.
Special Precautions
Patient with coagulation/bleeding disorders (e.g. thrombocytopenia), Guillain-Barré syndrome (within 6 weeks prior to receiving vaccination), immunodeficiency (e.g. HIV infection). Patients with complete primary vaccination or a booster dose in the previous 5 years. Postpone vaccination in patients with acute febrile illness. Children. Pregnancy and lactation.
Adverse Reactions
Significant: Syncope.
Blood and lymphatic system disorders: Lymphadenopathy.
Gastrointestinal disorders: Nausea.
General disorders and administration site conditions: Inj site reactions (e.g. pain, redness, bruising, swelling, induration), fever, malaise, irritability.
Musculoskeletal and connective tissue disorders: Arthralgia, myalgia.
Nervous system disorders: Neuritis, headache, dizziness.
Skin and subcutaneous tissue disorders: Rash.
Vascular disorders: Hypotension.
Potentially Fatal: Anaphylactoid or hypersensitivity reactions.
IM/Parenteral/SC: C
MonitoringParameters
Monitor for syncope, hypersensitivity reactions, 15 minutes after administration.
Drug Interactions
Increased risk of bleeding with anticoagulants. Decreased therapeutic effect and immune response with immunosuppressive therapies (e.g. high-dose corticosteroids).
Action
Description: Tetanus toxoid vaccine is a preparation of inactivated toxin produced by virulent tetanus bacilli (product of Clostridium tetani). It acts as antigen and produces active immunity against tetanus.
Duration: Immunity: Approx 10 years.
Storage
Store between 2-8°C. Do not freeze. Protect from light.
Any unused portions should be disposed of in accordance with local requirements.
ATC Classification
J07AM01 - tetanus toxoid ; Belongs to the class of tetanus bacterial vaccines.
Disclaimer: This information is independently developed by MIMS based on Vaccine, tetanus toxoid, tetanus toxoid adsorbed from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in